The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
|Articles|July 30, 2021
Pharmacy Clinical Pearl of the Day: Lipophilic Statins vs Hydrophilic Statins
Author(s)Saro Arakelians, PharmD
Lipophilic statins for dyslipidemia penetrate muscle more easily than hydrophilic statins and are associated with a higher incidence of adverse effects.
Advertisement
List of statins for dyslipidemia and lipophilic versus hydrophilic treatments:
- Fluvastatin (Lescol)
- Lovastatin (Mevacor, Altoprev)
- Pravastatin (Pravachol)
- Simvastatin (Zocor)
- Atorvastatin (Lipitor)
- Rosuvastatin (Crestor)
- Pitavastatin (Livalo)
Explanation:
- Myalgia may be related to lipophilicity (fat loving) and to high dosage, as well as interaction with other medications.
- Lipophilic statins penetrate muscle more easily than hydrophilic statins and are associated with a higher incidence of adverse effects, particularly myopathy, although reports of muscle toxicity, including rhabdomyolysis, have been reported with all statins.
- Hydrophilic statins stay out of muscle and brain tissue, which are fat filled.
Reference
Advertisement
Related to this article
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
About 89% of Americans live within 5 miles of a pharmacy, but proximity says little about whether they can afford their medications or get real counseling.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
3
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5